Address SGLT2 Inhibitor Use in the Hospital
September 2022
You’ll need to ensure appropriate use of SGLT2 inhibitors (empagliflozin, etc)...as more hospitals add these meds to formulary.
It’s partly because guidelines for heart failure with reduced ejection fraction (HFrEF) now recommend “quad therapy”...adding an SGLT2 inhibitor (SGLT2i) to triple therapy, regardless of diabetes.
Plus guidelines suggest an SGLT2i for patients with heart failure with mildly reduced EF (HFmrEF) or preserved EF (HFpEF).Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote